Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Ventyx Biosciences Inc (NASDAQ: VTYX) closed at $2.08 in the last session, up 2.97% from day before closing price of $2.02. In other words, the price has increased by $2.97 from its previous closing price. On the day, 1.47 million shares were traded. VTYX stock price reached its highest trading level at $2.125 during the session, while it also had its lowest trading level at $1.92.
Ratios:
We take a closer look at VTYX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 23.52 and its Current Ratio is at 23.52. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on March 12, 2024, Upgraded its rating to Overweight and sets its target price to $16 from $7 previously.
On March 12, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $12.
Wells Fargo Downgraded its Overweight to Equal Weight on November 07, 2023, whereas the target price for the stock was revised from $77 to $8.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 27 ’24 when Nuss John sold 21,119 shares for $2.36 per share. The transaction valued at 49,841 led to the insider holds 464,582 shares of the business.
Nuss John bought 21,119 shares of VTYX for $49,842 on Dec 27 ’24. On Dec 23 ’24, another insider, Gujrathi Sheila, who serves as the Director of the company, bought 130,000 shares for $2.31 each. As a result, the insider paid 300,573 and bolstered with 130,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VTYX now has a Market Capitalization of 147078256 and an Enterprise Value of -116710816.
Stock Price History:
The Beta on a monthly basis for VTYX is 0.53, which has changed by 0.03061223 over the last 52 weeks, in comparison to a change of 0.23171377 over the same period for the S&P500. Over the past 52 weeks, VTYX has reached a high of $11.48, while it has fallen to a 52-week low of $1.67. The 50-Day Moving Average of the stock is -7.89%, while the 200-Day Moving Average is calculated to be -26.19%.
Shares Statistics:
According to the various share statistics, VTYX traded on average about 1.68M shares per day over the past 3-months and 2063730 shares per day over the past 10 days. A total of 70.67M shares are outstanding, with a floating share count of 52.89M. Insiders hold about 25.20% of the company’s shares, while institutions hold 63.96% stake in the company. Shares short for VTYX as of 1735603200 were 9595973 with a Short Ratio of 5.72, compared to 1732838400 on 8590825. Therefore, it implies a Short% of Shares Outstanding of 9595973 and a Short% of Float of 15.890001000000002.
Earnings Estimates
A comprehensive evaluation of Ventyx Biosciences Inc (VTYX) is underway, with the input of 7.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.52, with high estimates of -$0.47 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$2.0 and -$2.18 for the fiscal current year, implying an average EPS of -$2.1. EPS for the following year is -$2.15, with 8.0 analysts recommending between -$1.76 and -$2.98.
